Company / Depreciation & Amortization
Lineage Cell Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$699.0K
FY2025
5-year range
$562.0K / $823.0K
FY2021-FY2025
Trend
+19.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has fluctuated over the past 10 years, ranging from $562,000 in FY2023 to $1M in FY2019.
Based on SEC 10-K filings.
$699,000 in FY2025 with a 5-year CAGR of -6.9%.
Increased from $562,000 to $699,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +1.8%
- 5-Year CAGR
- -6.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -6.9%, indicating a declining trend.
- In FY2025, depreciation & amortization increased 19.1% year-over-year.
- Peak depreciation & amortization was recorded in FY2019.
- Lowest depreciation & amortization in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $699.0K | +19.1% |
| FY2024 | $587.0K | +4.4% |
| FY2023 | $562.0K | -15.2% |
| FY2022 | $663.0K | -19.4% |
| FY2021 | $823.0K | -17.9% |
| FY2020 | $1.0M | -7.3% |
| FY2019 | $1.1M | +14.1% |
| FY2018 | $947.0K | -12.2% |
| FY2017 | $1.1M | +2.6% |
| FY2016 | $1.1M | +60.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026